Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2013

View Archived Issues

Isis earns milestone payment from GSK for designation of new development candidate

Antibody fragment-mediated eradication of hallmark Alzheimer-like pathology in transgenic mice

A comparison of systemic and macrophage receptor-targeted delivery of an anti-inflammatory drug

Ligase inhibitors that inhibit hormone-induced growth of endometrial cancer

First clinical data presented for ISIS-APOARx

Relvar Ellipta approved in Europe for asthma and COPD

Lupin discloses novel CRAC modulators

Pharmacokinetic data on novel natriuretic peptide ANX-042 reported

Suven presents novel candidates for cognitive deficits associated with degenerative diseases

Cellceutix identifies drug candidates for infections, completing IND for antipsoriatic drug

Novartis synthesizes new series of complement factor B inhibitors

FDA grants priority review to Merck & Co.'s NDA for intravenous Noxafil

RedHill Biopharma provides regulatory update for RHB-103

Columbia University prepares new RBP4 antagonists for AMD

Actinium Pharmaceuticals provides update on Iomab-B and Actimab-A

Researchers in Alabama synthesize novel LRRK2 inhibitors

Aileron Therapeutics secures financing to advance pipeline

A team of scientists at Merck KGaA disclose novel pyrrolotriazinone derivatives

Corgenix files concurrent de novo 510 pre-market notification for Hyaluronic Acid Test Kit

Qiagen and Lilly in new agreement to develop companion diagnostic for oncology compound

Generex Biotechnology reaches prespecified point in phase II trial of breast cancer vaccine

Teva Pharmaceutical provides updates to oncology biologic portfolio

Results from phase IIIb study of Xiaflex for Dupuytren's contracture with multiple palpable cords

European approval for Vitekta

European Commission approves Prilocaine Lidocaine Plethora for premature ejaculation

Kyorin launches Flutiform in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...